Hannah Tran's questions to Intellia Therapeutics Inc (NTLA) leadership • Q1 2025
Question
Hannah Tran, on behalf of Andy Chen, inquired about the company's consideration of non-dilutive financing options to extend its cash runway beyond the first half of 2027.
Answer
Chief Financial Officer Ed Dulac confirmed that multiple options are on the table. He highlighted that upcoming clinical and regulatory milestones will create opportunities for favorable capital raises. Potential levers include strategic collaborations for assets like NTLA-2002, royalty transactions as commercialization approaches, and venture or term debt structures.